PHI with Chronic ulcerative rectosigmoiditis
How does this condition affect your private health insurance?
Chronic Rectosigmoiditis Ulcerosa is a form of ulcerative colitis, a chronic inflammatory bowel disease (IBD) specifically affecting the rectum and sigmoid colon. It's characterized by inflammation and ulceration of the colon's innermost lining. Symptoms often include bloody diarrhea, urgency, tenesmus (a feeling of incomplete defecation), and abdominal pain. The disease follows a relapsing-remitting course, meaning periods of active symptoms (flares) are interspersed with periods of remission. While its exact cause is unknown, it's believed to involve a combination of genetic predisposition, environmental factors, and an aberrant immune response. Management focuses on controlling inflammation and maintaining remission.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Several weeks to months, often requiring hospitalization for severe flares.
Duration of Illness (Lifetime)
Chronic, lifelong disease with periods of remission and relapse.
Cost of Treatment (Initial)
High (e.g., 5,000-20,000+ USD) including diagnostics, medication (steroids, aminosalicylates), and potential hospitalization.
Cost of Treatment (Lifetime)
Very high (e.g., 50,000-500,000+ USD) due to ongoing medication, regular monitoring, potential biologics, and possible surgeries.
Mortality Rate
Low (1-3%) directly from the disease itself, but increases with severe complications like toxic megacolon or colorectal cancer.
Risk of Secondary Damages
Moderate to High (30-60%) for anemia, malnutrition, arthritis, skin lesions, psychological distress (anxiety, depression); low for severe complications like toxic megacolon or increased colorectal cancer risk in long-standing disease.
Probability of Full Recovery
Very low (less than 5%) without colectomy; remission is the primary goal with medical therapy. Colectomy offers a surgical cure for colonic symptoms.
Underlying Disease Risk
Low to Moderate (10-20%) for other autoimmune conditions (e.g., primary sclerosing cholangitis, ankylosing spondylitis), or irritable bowel syndrome overlap.